Evidence map›Paper›PMID 37175001›Full record

ArticleDiagnostics (Basel, Switzerland)2023

The GRPR Antagonist [

Ayman Abouzayed, Jesper Borin, Fanny Lundmark, Anastasiya Rybina, Sophia Hober, Roman Zelchan, Vladimir Tolmachev, Vladimir Chernov, Anna Orlova

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Ayman AbouzayedDepartment of Medicinal Chemistry, Uppsala University, 751 83 Uppsala, Sweden.
Jesper BorinDepartment of Protein Science, KTH Royal Institute of Technology, 114 17 Stockholm, Sweden.
Fanny LundmarkDepartment of Medicinal Chemistry, Uppsala University, 751 83 Uppsala, Sweden.ORCID 0000-0002-9153-2832
Anastasiya RybinaDepartment of Nuclear Medicine, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 634009 Tomsk, Russia.
Sophia HoberDepartment of Protein Science, KTH Royal Institute of Technology, 114 17 Stockholm, Sweden.ORCID 0000-0003-0605-8417
Roman ZelchanDepartment of Nuclear Medicine, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 634009 Tomsk, Russia.
Vladimir TolmachevDepartment of Immunology, Genetics and Pathology, Uppsala University, 752 37 Uppsala, Sweden.ORCID 0000-0002-6122-1734
Vladimir ChernovDepartment of Nuclear Medicine, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 634009 Tomsk, Russia.
Anna OrlovaDepartment of Medicinal Chemistry, Uppsala University, 751 83 Uppsala, Sweden.ORCID 0000-0001-6120-2683
Uppsala University · SERussian Academy of Sciences · RUKTH Royal Institute of Technology · SE

Funding

Ministry of Health and Higher Education of the Russian Federation 075-15-2022-1103Swedish Cancer Society 20 0814 UsFSwedish Cancer Society 20-0815 PjFSwedish Research Council 2019-00986Swedish Research Council 2022-00556TPU development program Priority 2030 ИЗ-042-1308-2022
6 · The paper itself

Abstract

Gastrin-releasing peptide receptors (GRPRs) are overexpressed in the majority of primary prostate tumors and in prostatic lymph node and bone metastases. Several GRPR antagonists were developed for SPECT and PET imaging of prostate cancer. We previously reported a preclinical evaluation of the GRPR antagonist [

Indexed as

GRPR antagonistprostate cancersterilitytechnetium-99mtoxicity testing

Identifiers

PMID37175001
PMCPMC10178091
OpenAlexW4368406957

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.